NBIX vs STAA: fair value comparison
Neurocrine Biosciences, Inc. and STAAR Surgical Company · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, STAA currently sits closer to the top of our discount ranking. NBIX carries the stronger quality grade.
| NBIX | STAA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $166.23 | $24.34 |
| 12-month range | $131.78–$167.77 | $18.04–$29.55 |
| Sector rank | #18 of 113 Healthcare | #13 of 113 Healthcare |
| Quality grade | C+ | D |
| Leverage | Low | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: NBIX fair value analysis · STAA fair value analysis